Enanta Pharmaceuticals (ENTA) FCF Margin (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted FCF Margin of 41.7% for Q1 2026, up 33.64% on a QoQ basis from 62.85% in Q4 2025, and up 10799.0% year-over-year from N/an in Q1 2025.
Enanta Pharmaceuticals (ENTA) FCF Margin (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' FCF Margin history runs 15 years deep, the most recent figure standing at 41.7% for Q1 2026.
- Quarterly FCF Margin rose 10799.0% year-over-year to 41.7% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.98% (up 11287.0% YoY) and the FY2025 annual result came in at 29.5%, up 9523.0% from the prior year.
- FCF Margin was 41.7% for Q1 2026 at Enanta Pharmaceuticals, up from 62.85% in the prior quarter.
- Across five years, FCF Margin topped out at 94.74% in Q2 2025 and bottomed at 202.24% in Q2 2023.
- A 5-year average of 96.09% and a median of 113.38% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin plunged 11822 bps — and 2025, when it surged 15754 bps.
- Enanta Pharmaceuticals' FCF Margin stood at 151.14% in 2022, then increased by 6 bps to 141.46% in 2023, then increased by 20 bps to 113.38% in 2024, then soared by 45 bps to 62.85% in 2025, then jumped by 34 bps to 41.7% in 2026.
- Business Quant data shows ENTA's FCF Margin at 41.7% in Q1 2026, 62.85% in Q4 2025, and 32.72% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.45% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - | -41.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.70% |
| Dec 31, 2025 | -62.85% |
| Sep 30, 2025 | 32.72% |
| Jun 30, 2025 | 94.74% |
| Mar 31, 2025 | -149.70% |
| Dec 31, 2024 | -113.38% |
| Sep 30, 2024 | -114.29% |
| Jun 30, 2024 | -62.80% |
| Mar 31, 2024 | -181.27% |
| Dec 31, 2023 | -141.46% |
| Sep 30, 2023 | -74.05% |
| Jun 30, 2023 | -202.24% |
| Mar 31, 2023 | -86.48% |
| Dec 31, 2022 | -151.14% |
| Sep 30, 2022 | -84.89% |
| Jun 30, 2022 | -153.19% |
| Mar 31, 2022 | -141.61% |
| Dec 31, 2021 | -48.17% |
| Sep 30, 2021 | -89.17% |
| Jun 30, 2021 | -134.98% |